EndoPredict is a leading breast cancer recurrence test.
From a patient’s perspective selecting the best available test is often critical to getting the best treatment possible. Here’s how EndoPredict stands out from other available tests.
Extremely importantly: EndoPredict is the only test to have validated the benefit of taking chemotherapy in ~3700 patients. Oncotype DX is validation is only ~1000 patients. Unlike EndoPredict, which validated with the newer chemotherapy options, Oncotype DX validation covers older chemotherapy options. None of the other tests offer this validation or findings.
2. 15 Year Benefit
EndoPredict is the only test which offers 5-15 year benefit of taking endocrine therapy. Breast Cancer Index offer this result from 5-10 year. None of the other tests give this valuable clinical information.
3. Same Cutoff
Most tests change the cutoff for different patient types, creating a confusing and questionable scenario for patients and doctors. EndoPredict uses the same cutoff for every patient thereby provides an answer for every patient.